Related Experiment Video

Updated: Apr 22, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.2K

MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis

Robert N Booher1, Harold Hatch1, Brian M Dolinski1

  • 1Discovery Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America.

Plos One
|October 8, 2014
PubMed

Insights

Dinaciclib effectively inhibits cancer cell growth by inducing apoptosis, primarily through the downregulation of MCL1. This mechanism suggests MCL1 and BCL-xL as key biomarkers for predicting patient response to dinaciclib therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Dinaciclib is a cyclin-dependent kinase (CDK) inhibitor investigated for cancer treatment.
  • Understanding dinaciclib's antitumor mechanisms and identifying predictive biomarkers are crucial for its clinical development.

Purpose of the Study:

  • To elucidate the primary antitumor mechanism of dinaciclib.
  • To identify predictive biomarkers for dinaciclib efficacy.
  • To explore combination therapies involving dinaciclib.

Main Methods:

  • In vitro and in vivo studies assessing dinaciclib's effects on cell cycle progression and apoptosis.
  • Pharmacokinetic analysis in mouse and human models.
  • Evaluation of BCL2 family member expression, specifically MCL1 and BCL-xL.
  • Assessment of synergistic effects with navitoclax (ABT-263).

Main Results:

  • Dinaciclib effectively blocks cell cycle progression and induces apoptosis, with apoptosis being the main antitumor mechanism.
  • Dinaciclib treatment leads to the downregulation of MCL1, an antiapoptotic protein.
  • Sensitivity to dinaciclib correlates with the MCL1-to-BCL-xL mRNA ratio or MCL1 amplification in solid tumor models.
  • Synergy was observed between dinaciclib and navitoclax, a BCL2 family inhibitor.

Conclusions:

  • Apoptosis induction, mediated by MCL1 downregulation, is a key antitumor mechanism of dinaciclib.
  • MCL1 and BCL-xL are potential predictive biomarkers for dinaciclib response.
  • Combination therapy with BCL2 family member inhibitors warrants further investigation.

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

3.4K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

10.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.1K
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
33